Literature DB >> 2515604

Elimination of native and carbohydrate-modified tissue plasminogen activator in rabbits.

M Einarsson1, L Hggroth, C Mattsson.   

Abstract

The elimination of native and carbohydrate-modified tissue type plasminogen activator (t-PA) after an i.v. bolus injection was studied in rabbits. t-PA with a low content of mannose (man-t-PA) was obtained by treatment with alpha-mannosidase, which cleaves terminal mannose from the carbohydrate side chains of the molecule. About 50% of the total mannose was removed from the native t-PA. Clearance of t-PA in rabbits was followed by measurements of both the fibrinolytic activity of the activators and the radioactivity of the iodine-labelled compounds. A biphasic mode of elimination of the fibrinolytic activity as well as the radioactivity was found with both the native and the carbohydrate modified t-PA. The initial half-life (t 1/2 alpha) was the same, about 1.5 minutes, for both compounds, irrespective of method of analysis. The late half-life (t 1/2 beta) was also the same, about 15 minutes, for both compounds. However, the beta-elimination of native t-PA could only be determined accurately from radioactivity data in the dosages tested, i.e. up to 2 mg of t-PA. No dose dependency in the elimination pattern was observed. In gel filtration experiments, with plasma from the rabbits, it was demonstrated that in addition to fibrinolytically active t-PA and man-t-PA, both fibrinolytically inactive high molecular weight complexes and low molecular weight degradation products of the activators were present in plasma after injection of the compounds. The second phase of elimination (beta) was much more pronounced after mannosidase treatment of the t-PA.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515604

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.

Authors:  P Fitch; B Bennett; N A Booth; A Croll; S W Ewen
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

2.  Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.

Authors:  U Martin; S Fischer; U Kohnert; U Opitz; R Rudolph; G Sponer; A Stern; K Strein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

3.  Characterization of the binding of plasminogen activators to plasma membranes from human liver.

Authors:  G Nguyen; S J Self; C Camani; E K Kruithof
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.